

### Remarks

Applicants hereby request entry into the national stage and examination of the above-identified application.


The specification has been amended to correct an error in the specification. Specifically, Table 1 has been amended to reflect that the peptide sequences PCP-1, PCP-2, PCP-3, and PCP-4 contain L-amino acids. The sequences as originally presented were in upper case, thereby designating D-amino acids, which is in error. These four peptides are reported in WO 99/32640, which is incorporated by reference into the specification. Because these peptides as described in WO 99/32640 contain L-amino acids, *see, e.g.*, Example 1 thereof which describes their expression in host cells, the above amendments can be made without entry of new matter.

With respect to the amendments to the claims, claims 3-6, 8, 9, 18, and 19 have been amended, and new claims 23-29 have been introduced. The amendments to the claims were made either to correct informalities or to remove multiple dependencies, with the exception of claim 5, which was amended to rectify the above-noted error in the sequences of PCP-1, PCP-2, PCP-3, and PCP-4. New claims 23-29 find descriptive support in original claims 18 and 19. No new matter has been entered by way of these amendments.

In view of all of the foregoing, applicants respectfully request examination of the entirety of the claimed subject matter.

Respectfully submitted,

Date: October 15, 2004

  
\_\_\_\_\_  
Edwin V. Merkel  
Registration No. 40,087

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1128  
Facsimile: (585) 263-1600